MAIA plans Phase 3 pivotal trial of THIO+CPI vs chemo in NSCLC patients

MAIA Biotechnology, Inc.

Phase 3 trial THIO-104 to enroll up to 300 patients with third-line NSCLC.
Primary endpoint is overall survival; THIO sequenced with checkpoint inhibitor vs investigator's choice chemo.
Patient enrollment expected to begin H2 2025 in Asia, Europe, and U.S.
Based on THIO-101 Phase 2 data that consistently outperformed standard options.
Trial designed to support FDA commercial approval of THIO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.